Tipranavir: A Ritonavir-Boosted Protease InhibitorA Viewpoint by Dushyantha T. Jayaweera

被引：0
|
作者：
Dushyantha T. Jayaweera
机构：
[1] University of Miami,Division of Infectious Diseases, Department of Medicine
来源：
Drugs | 2005年 / 65卷
关键词：
Ritonavir; Salvage Therapy; Gastrointestinal Toxicity; Lopinavir; Pivotal Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1678 / 1679
页数：1
相关论文
共 50 条
  • [21] Effectiveness of monotherapy with a ritonavir-boosted protease inhibitor for HIV patients in clinical practice
    Moron Romero, Rocio
    Valle, Margarita
    Rodriguez, Alejandro
    Nieto, Pelayo
    Casas, Inmaculada
    Cabeza, Jose
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 330 - 330
  • [22] Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection
    Sahali, Sabrinel
    Chaix, Marie-Laure
    Delfraissy, Jean-Francois
    Ghosn, Jade
    AIDS REVIEWS, 2008, 10 (01) : 4 - 14
  • [23] Neurocognitive function in patients with high bilirubinaemia receiving ritonavir-boosted protease inhibitors
    Barber, T.
    Hill, A.
    Yapa, H.
    Higgs, C.
    Cocker, A.
    Moyes, A.
    Boffito, M.
    Moyle, G.
    HIV MEDICINE, 2014, 15 : 72 - 73
  • [24] Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy
    Lichterfeld, M
    Wöhrmann, A
    Schmeisser, N
    Fätkenheuer, G
    Salzberger, B
    Wyen, C
    Schmitz, K
    Sauerbruch, T
    Rockstroh, JK
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2003, 8 (02) : 56 - 60
  • [25] Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
    Justen Manasa
    Vici Varghese
    Sergei L. Kosakovsky Pond
    Soo-Yon Rhee
    Philip L. Tzou
    W. Jeffrey Fessel
    Karen S. Jang
    Elizabeth White
    Thorsteinn Rögnvaldsson
    David A. Katzenstein
    Robert W. Shafer
    Scientific Reports, 7
  • [26] Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
    Manasa, Justen
    Varghese, Vici
    Pond, Sergei L. Kosakovsky
    Rhee, Soo-Yon
    Tzou, Philip L.
    Fessel, W. Jeffrey
    Jang, Karen S.
    White, Elizabeth
    Rognvaldsson, Thorsteinn
    Katzenstein, David A.
    Shafer, Robert W.
    SCIENTIFIC REPORTS, 2017, 7
  • [27] Neurocognitive function in patients with or without high bilirubinaemia receiving ritonavir-boosted protease inhibitors
    Barber, T. J.
    Hill, A.
    Yapa, H.
    Boffito, M.
    Moyle, G.
    ANTIVIRAL THERAPY, 2014, 19 : A47 - A47
  • [28] Coadministration of boceprevir with ritonavir-boosted HIV protease inhibitors could reduce drugs' effectiveness
    不详
    FORMULARY, 2012, 47 (03) : 105 - +
  • [29] Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers
    Mukwaya, G
    MacGregor, T
    Hoelscher, D
    Heming, T
    Legg, D
    Kavanaugh, K
    Johnson, P
    Sabo, JP
    McCallister, S
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) : 4903 - 4910
  • [30] Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
    Costarelli, Silvia
    Cozzi-Lepri, Alessandro
    Lapadula, Giuseppe
    Bonora, Stefano
    Madeddu, Giordano
    Maggiolo, Franco
    Antinori, Andrea
    Gori, Andrea
    D'Arminio-Monforte, Antonella
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 56 - 57
12345